{"status": "Ok", "redirect_url": "https://www.businesswire.com/news/home/20260613831839/en/Results-from-Incyte%E2%80%99s-Pivotal-Phase-3-frontMIND-Trial-of-Tafasitamab-Monjuvi%C2%AEMinjuvi%C2%AE-Combination-Presented-at-the-2026-European-Hematology-Association-EHA-Congress-Plenary-Showed-Prolonged-Progression-Free-Survival", "message": "News view counter 798397 successfully enlarged"}